Pharmaceutical giant Eli Lilly and Company will purchase four-year-old Disarm Therapeutics, a Cambridge-based biotechnology company, for $135 million up front.  Investors reportedly could receive an additional $1.225 billion depending on the success of Lilly’s development and commercialization efforts relating to the new drugs resulting from the deal.

Disarm has reportedly developed certain drug therapies for  axonal degeneration, a common feature of many neurological disorders. The development included the discovery of a protein that causes axonal degeneration and molecules known as SARM1 inhibitors which the developers believe can address axonal degeneration. Diseases targeted for the therapies include multiple sclerosis and ALS.

Disarm was reportedly founded by Atlas Venture, Atlas Entrepreneurs-in-Residence Dr. Rajesh Devraj and Dr. Raul Krauss, Drs. DiAntonio and Milbrandt of Washington University School of Medicine in St. Louis. AbbVie Ventures and Lightstone Ventures co-invested with Atlas to support the foundational work at Disarm.

Related articles: STAT News   The Financial  Fierce Biotech

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Dan Shores Dan Shores

Dan Shores is a Partner at Rothwell Figg.  Dan is a dedicated patent lawyer and strategist who believes in his clients and the power of their ideas. He focuses on serving biotech, medical device, energy, software, cybersecurity, and other technology-based companies and understands

Dan Shores is a Partner at Rothwell Figg.  Dan is a dedicated patent lawyer and strategist who believes in his clients and the power of their ideas. He focuses on serving biotech, medical device, energy, software, cybersecurity, and other technology-based companies and understands the myriad of challenges that such companies face when breaking through and establishing themselves in their respective markets. Dan works with clients to build robust patent portfolios, protect trade secrets, negotiate strategic collaborations, conduct due diligence and landscape investigations, and prepare for success in funding rounds and exits. An engineer by education, and having extensive experience in transactional, litigation, procurement, and strategic counseling matters for technology-based companies, Dan is a problem-solver who excels at deciphering key translational aspects of a broad array of technologies to maximize leverage in the context of clients’ desired implementation of such technologies whether as participants in dynamic markets or as first movers.

Dan has served companies utilizing the following technologies (without limitation): mRNA therapies; lipid nanoparticle delivery technologies; genetically engineered swine and organs for xenotransplantation; artificial intelligence for drug discovery; CAR-T therapies; oligonucleotide development; pharmaceutical treatment of rhinitis with levocetirizine; pharmaceutical treatment of hepatitis B with telbivudine; genetically-modified cotton seed; fiber-optic probes for tissue investigation; implantable glucose-sensing devices; high throughput genetic seed-chipping technology; cybersecurity threat assessment platforms; interactive media systems for healthcare institutions; artificial intelligence (various applications); identification systems for cable-based medical devices; identification of digital positions of interest on media items; heat-treated glass with multilayer low-emissivity coatings; automotive and agricultural equipment; pressure-sensitive adhesives; three dimensional printing of buildings and other structures; and integrated electronic securities marketplace systems.

Dan is a registered patent attorney licensed to practice before the United States Patent and Trademark Office, and is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts. Dan lives in Boston with his wife Lindsay and their two English Bulldogs Jarves and Rosie.